BR112024002215A2 - Composição à base de lipídios para administração oral de antagonistas do receptor b2 da bradicinina - Google Patents
Composição à base de lipídios para administração oral de antagonistas do receptor b2 da bradicininaInfo
- Publication number
- BR112024002215A2 BR112024002215A2 BR112024002215A BR112024002215A BR112024002215A2 BR 112024002215 A2 BR112024002215 A2 BR 112024002215A2 BR 112024002215 A BR112024002215 A BR 112024002215A BR 112024002215 A BR112024002215 A BR 112024002215A BR 112024002215 A2 BR112024002215 A2 BR 112024002215A2
- Authority
- BR
- Brazil
- Prior art keywords
- bradykinin
- oral administration
- lipid
- based composition
- receptor antagonists
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940123765 Bradykinin B2 receptor antagonist Drugs 0.000 title abstract 3
- 239000003359 bradykinin B2 receptor antagonist Substances 0.000 title abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- ZTCLCSCHTACERP-WTDRUJNCSA-N N-[(1S)-1-[3-chloro-5-fluoro-2-[[2-methyl-4-(2-methyl-1,2,4-triazol-3-yl)quinolin-8-yl]oxymethyl]phenyl]-1-deuterioethyl]-2-(difluoromethoxy)acetamide Chemical compound [2H][C@](C)(C1=C(C(=CC(=C1)F)Cl)COC=1C=CC=C2C(=CC(=NC=12)C)C1=NC=NN1C)NC(COC(F)F)=O ZTCLCSCHTACERP-WTDRUJNCSA-N 0.000 abstract 1
- 229920002675 Polyoxyl Polymers 0.000 abstract 1
- 239000004359 castor oil Substances 0.000 abstract 1
- 235000019438 castor oil Nutrition 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
- 229910052739 hydrogen Chemical group 0.000 abstract 1
- 239000001257 hydrogen Chemical group 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
composição à base de lipídios para administração oral de antagonistas do receptor b2 da bradicinina. a invenção se refere a composições farmacêuticas para administração oral que compreende um antagonista do receptor b2 da bradicinina (bk) que tem uma estrutura química de acordo com a fórmula 1, ou um sal ou solvato do mesmo, em que r é deutério ou hidrogênio: fórmula (1), como (s)-n-(1-deutero-1-(3-cloro-5-fluoro-2-((2-metil-4-(1-metil-1h-1,2,4-triazol-5-il)quinolin-8-iloxi)metil)fenil)etil)-2-(difluorometoxi)acetamida. as composições compreendem o antagonista do receptor b2 de bk em uma forma dissolvida em um veículo líquido que compreende monocaprilato de propilenoglicol, óleo de rícino polioxil e propilenoglicol. além disso, são fornecidos usos terapêuticos das composições.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21189990 | 2021-08-05 | ||
| PCT/EP2022/072049 WO2023012322A1 (en) | 2021-08-05 | 2022-08-05 | Lipid-based composition for oral administration of bradykinin b2-receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112024002215A2 true BR112024002215A2 (pt) | 2024-04-30 |
Family
ID=77226756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112024002215A BR112024002215A2 (pt) | 2021-08-05 | 2022-08-05 | Composição à base de lipídios para administração oral de antagonistas do receptor b2 da bradicinina |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP4203919B1 (pt) |
| KR (1) | KR20240039185A (pt) |
| CN (1) | CN118076342A (pt) |
| AU (1) | AU2022323749A1 (pt) |
| BR (1) | BR112024002215A2 (pt) |
| CA (1) | CA3227476A1 (pt) |
| CO (1) | CO2024001171A2 (pt) |
| DK (1) | DK4203919T3 (pt) |
| FI (1) | FI4203919T3 (pt) |
| HR (1) | HRP20240525T1 (pt) |
| IL (1) | IL310321A (pt) |
| LT (1) | LT4203919T (pt) |
| PL (1) | PL4203919T3 (pt) |
| PT (1) | PT4203919T (pt) |
| RS (1) | RS65427B1 (pt) |
| TW (1) | TW202320774A (pt) |
| WO (1) | WO2023012322A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117224522B (zh) * | 2023-11-15 | 2024-02-23 | 北京协和药厂有限公司 | 药物组合物及其制备方法、药物制剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0807105B1 (en) | 1994-10-27 | 2004-06-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| CA2319730A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Bradykinin antagonists |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| JP2010508357A (ja) * | 2006-10-31 | 2010-03-18 | ワイス エルエルシー | ホスホリパーゼ酵素阻害剤の処方 |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| KR20150127718A (ko) | 2013-03-14 | 2015-11-17 | 샤이어 휴먼 지네틱 테라피즈 인크. | Ｂ2-브라디키닌 수용체 매개 혈관부종의 치료 방법 |
| EP3998259A1 (en) | 2017-11-24 | 2022-05-18 | Pharvaris Netherlands B.V. | Novel bradykinin b2 receptor antagonists |
-
2022
- 2022-08-05 KR KR1020247007280A patent/KR20240039185A/ko unknown
- 2022-08-05 WO PCT/EP2022/072049 patent/WO2023012322A1/en active Application Filing
- 2022-08-05 BR BR112024002215A patent/BR112024002215A2/pt unknown
- 2022-08-05 TW TW111129507A patent/TW202320774A/zh unknown
- 2022-08-05 CN CN202280067108.5A patent/CN118076342A/zh active Pending
- 2022-08-05 HR HRP20240525TT patent/HRP20240525T1/hr unknown
- 2022-08-05 FI FIEP22760986.4T patent/FI4203919T3/fi active
- 2022-08-05 PL PL22760986.4T patent/PL4203919T3/pl unknown
- 2022-08-05 AU AU2022323749A patent/AU2022323749A1/en active Pending
- 2022-08-05 RS RS20240456A patent/RS65427B1/sr unknown
- 2022-08-05 EP EP22760986.4A patent/EP4203919B1/en active Active
- 2022-08-05 CA CA3227476A patent/CA3227476A1/en active Pending
- 2022-08-05 LT LTEPPCT/EP2022/072049T patent/LT4203919T/lt unknown
- 2022-08-05 IL IL310321A patent/IL310321A/en unknown
- 2022-08-05 PT PT227609864T patent/PT4203919T/pt unknown
- 2022-08-05 DK DK22760986.4T patent/DK4203919T3/da active
-
2024
- 2024-02-05 CO CONC2024/0001171A patent/CO2024001171A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL310321A (en) | 2024-03-01 |
| WO2023012322A1 (en) | 2023-02-09 |
| CN118076342A (zh) | 2024-05-24 |
| CA3227476A1 (en) | 2023-02-09 |
| FI4203919T3 (fi) | 2024-05-03 |
| EP4203919B1 (en) | 2024-01-31 |
| EP4203919A1 (en) | 2023-07-05 |
| HRP20240525T1 (hr) | 2024-07-05 |
| PL4203919T3 (pl) | 2024-06-10 |
| CO2024001171A2 (es) | 2024-05-20 |
| DK4203919T3 (da) | 2024-04-29 |
| PT4203919T (pt) | 2024-04-23 |
| KR20240039185A (ko) | 2024-03-26 |
| AU2022323749A1 (en) | 2024-02-08 |
| RS65427B1 (sr) | 2024-05-31 |
| TW202320774A (zh) | 2023-06-01 |
| LT4203919T (lt) | 2024-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10702499B2 (en) | Use of NK-1 receptor antagonists in pruritus | |
| US10617671B2 (en) | Use of NK-1 receptor antagonist serlopitant in pruritus | |
| AU2014302694B2 (en) | Use of NK-1 receptor antagonist serlopitant in pruritus | |
| BRPI0511967B8 (pt) | derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende | |
| BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| BR112015004244A2 (pt) | composição médica oralmente administrada | |
| CL2012000925A1 (es) | Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras. | |
| AR107828A1 (es) | 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k | |
| CO2024001171A2 (es) | Composición lipídica para la administración oral de antagonistas del receptor de bradicinina b2 | |
| BR112012029064A2 (pt) | formulação farmacêutica na forma de comprimidos de duas camadas compreendendo inibidores da hmg-coa redutase e irbesartan | |
| BRPI0912112B8 (pt) | composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica | |
| GT201300144A (es) | Composiciones farmaceuticas | |
| BRPI0716214A2 (pt) | Composições farmacêuticas para o tratamento de infecções fúngicas. | |
| ES2950461T3 (es) | Agente preventivo y/o terapéutico que contiene un compuesto de ácido piridilaminoacético para el tratamiento de una enfermedad que involucra una presión intraocular muy elevada | |
| PE20231945A1 (es) | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados | |
| ES2963706T3 (es) | Masitinib para el tratamiento del cáncer de próstata resistente a la castración | |
| MX2024000239A (es) | Medicamentos que comprenden inhibidores de la glicosidasa. | |
| WO2023278977A1 (en) | Compounds and methods for degrading rcor1, lsd1, hdac1 and hdac2 in the corest | |
| US20200121695A1 (en) | Compositions and methods for treating itch, skin inflammation, and pruritus |